ReviewLancet (London, England)2020
New directions in the treatment of opioid withdrawal.
Review in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05712707 (Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal), which is not on this map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of non-opioid interventions to reduce opioid withdrawal symptoms in patients with chronic pain: a systematic review.Family practice · 2022Pooled it
- Beneficial effects of the rapid vs. standard procedure for injection naltrexone initiation operate through increased adjunctive medication use.Drug and alcohol dependence · 2026Trial
- Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone.Experimental and clinical psychopharmacology · 2025Trial
- Usability and Quality of UCISAB, a Clinical Decision Support System for Optimization of Analgesia and Sedation Infusions in the ICU: A Multicenter, Cross-Sectional, Mixed-Methods Usability Evaluation in Colombia.Journal of clinical medicine · 2026Article
- A widespread internal brain state for fentanyl withdrawal.bioRxiv : the preprint server for biology · 2026Article
- Transcranial photobiomodulation with near-infrared laser induces analgesia in rats.The Journal of physiology · 2026Article
- Barriers to Buprenorphine Initiation in Patients Using Fentanyl.JAMA network open · 2026Article
- Case Report: Delirium and complications resulting from the abuse of compound liquorice tablets.Frontiers in psychiatry · 2026Article
- Buprenorphine Substitution as a Tapering Strategy for Opioid Discontinuation in Patients with Chronic Pain: A Nonrandomized and Proof of Concept Study.Pain and therapy · 2025Article
- Sex-specific role of the 5-HTNature communications · 2025Article
- Biochemical Identification and Clinical Description of Medetomidine Exposure in People Who Use Fentanyl in Philadelphia, PA.International journal of molecular sciences · 2025Article
- High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study.Addiction science & clinical practice · 2025Article
- Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders.Medical gas research · 2025Review
- Sustained Release of αO-Conotoxin GeXIVA[1,2] via Hydrogel Microneedle Patch for Chronic Neuropathic Pain Management.Marine drugs · 2025Article
- Outpatient-based buprenorphine-assisted opioid withdrawal management: A preliminary prospective observational study.Indian journal of psychiatry · 2025Article
- Noninvasive Brain Stimulation for Opioid Use Disorder: An Update of the Literature.Current behavioral neuroscience reports · 2025Article
- Similarities and Differences in Neurobiology.Advances in experimental medicine and biology · 2025Review
- The Genetic Association Between Prescription Pain Medication Use and the Risk for Fibromyalgia: A Bidirectional and Multivariable Mendelian Randomization Analysis.Journal of pain research · 2025Article
- Therapeutic Potential of Black Seed and Opium Poppy Oils in Mitigating Morphine Withdrawal Syndrome in an Animal Model.Addiction & health · 2025Article
- Dry eye disease and psychosomatics-benefits of mind-body therapy for dry eye disease.Frontiers in medicine · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The treatment of opioid withdrawal is an important area of clinical concern when treating patients with chronic, non-cancer pain, patients with active opioid use disorder, and patients receiving medication for opioid use disorder. Current standards of care for medically supervised withdrawal include treatment with μ-opioid receptor agonists, (eg, methadone), partial agonists (eg, buprenorphine), and α2-adrenergic receptor agonists (eg, clonidine and lofexidine). Newer agents likewise exploit these pharmacological mechanisms, including tramadol (μ-opioid receptor agonism) and tizanidine (α2 agonism). Areas for future research include managing withdrawal in the context of stabilising patients with opioid use disorder to extended-release naltrexone, transitioning patients with opioid use disorder from methadone to buprenorphine, and tapering opioids in patients with chronic, non-cancer pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.